TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00156195
Drug: Asoprisnil
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Tablet, oral Daily for 12 months
Study: NCT00156195
Drug: Asoprisnil
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg Tablet, oral Daily for 12 months
Study: NCT02569853
Drug: DFN-11
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
DrugBank: Avobenzone (DB09495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03448211
Drug: Para-toluenesulfonamide Injection (PTS)
Normalized name: o-toluenesulfonamide
DrugBank: p-Toluenesulfonamide (DB17299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection
Study: NCT02332811
Drug: sevelamer carbonate 800mg
Normalized name: SEVELAMER CARBONATE 800MG TAB
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT02332811
Drug: sevelamer carbonate 2.4 g
Normalized name: SEVELAMER CARBONATE 2.4 g ORAL POWDER, FOR SUSPENSION
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:powder~Route of administration: oral
Study: NCT01609595
Drug: sodium 2,2 dimethylbutyrate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
Study: NCT01997164
Drug: Intravitreal Aflibercept Injection (IAI)
Normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03768037
Drug: Anlotinib plus Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anlotinib p.o, qd and it should be continued until disease progress or unacceptable toxic effects.~Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
Study: NCT03768037
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
Study: NCT01137890
Drug: Zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eight capsules administered daily in split doses at 22:00 and 09:00.
Study: NCT01137890
Drug: Cocaine Hydrochloride
Normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
Study: NCT00073125
Drug: ABT-510/Thrombospondin-1 mimetic
DrugBank: ABT-510 (DB05434)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03410654
Drug: Tacrolimus, Extended Release, (Envarsus Xr)
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After conversion of tacrolimus immediate release to tacrolimus extended release.
Study: NCT03352765
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.
Study: NCT03352765
Drug: bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: bendamustine 160 mg/m2 intravenously on days -3 and -2
Study: NCT03352765
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.
Study: NCT01646827
Drug: Aripiprazole IM Depot
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One injection of 400 mg aripiprazole IM depot
Study: NCT02789982
Drug: β-adrenergic blocker propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02303262
Drug: Mocetinostat
Normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mocetinostat is taken orally at 70 mg/dose, 3 days per week, during cycle 1. Dose is increased to 90 mg starting at cycle 2.
Study: NCT02303262
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is administered via intravenous infusion at 1,000 mg/m2 at a rate of approximately 10 mg/m2/minute, on days 5 and 12 of every cycle.
Study: NCT00003888
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003888
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00883675
Drug: Docetaxel-Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
Study: NCT00590681
Drug: Bevacizumab and Temozolomide
Normalized name: Temozolomide
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
Study: NCT03896633
Drug: brinzolamide 1% ophthalmic suspension
Normalized name: Brinzolamide 1% Ophthalmic Suspension
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: brinzolamide 1% ophthalmic suspension
Study: NCT00508456
Drug: Temodar (Temozolomide)
Normalized name: temozolomide Injection [Temodar]
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m\^2 orally once a day for 7 consecutive days (days 8 through 15).
Study: NCT02958865
Drug: PF-06651600 or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Delivered orally for 8 weeks.
Study: NCT02958865
Drug: PF-06700841 or Placebo
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered orally for 8 weeks.
Study: NCT02958865
Drug: PF-06700841
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered orally for 24 weeks.
Study: NCT02958865
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered orally for 24 weeks.
Study: NCT00827983
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg, s.c., once à day
Study: NCT00827983
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90 mg, vaginally, once à day
Study: NCT00427700
Drug: clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg PO on days 5-9 of the menstrual cycle
Study: NCT00427700
Drug: raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg PO on days 5-9 of the menstrual cycle
Study: NCT00923910
Drug: WT1 Peptide-Pulsed Dendritic Cells
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00923910
Drug: Donor Lymphocytes
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
Study: NCT03498716
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.~Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year
Study: NCT03498716
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered by IV, 80 mg/m\^2 every week for 12 weeks.
Study: NCT00934921
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 8 mg Orally Disintegrating Tablet
Study: NCT02406651
Drug: Recombinant Human Interleukin-22 IgG2-Fc (F-652)
Normalized name: Recombinant Human Interleukin-12
DrugBank: Eflepedocokin alfa (DB16366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of reconstitution lyophilized F-652.
Study: NCT04595513
Drug: TAVT-18 (sirolimus)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The investigational drug product to be used in this study is TAVT-18, a proprietary formulation of sirolimus in clinical development, by Tavanta Therapeutics, Inc. It is provided in a powder formulation in pre-measured vials.
Study: NCT01815125
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
Study: NCT00212602
Drug: ONO-7436
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03467113
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol
Study: NCT00923910
Drug: IL-4
Normalized name: IL-4
DrugBank: Binetrakin (DB12182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
Study: NCT02783833
Drug: MMV390048 dose to be determined mg
Normalized name: olopatadine
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
Study: NCT02248571
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered as combined therapy with Capecitabine
Study: NCT02248571
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered as combined therapy with Exemestane
Study: NCT02248571
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered as combined therapy with Everolimus
Study: NCT00003562
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003562
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03616821
Drug: Brazikumab
Normalized name: Brazikumab
DrugBank: Brazikumab (DB16115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
Study: NCT00475098
Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment in lung tumours
Study: NCT03813979
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intake of a single-dose dolutegravir 50 mg tablet on an empty stomach
Study: NCT01017614
Drug: Monofer
Normalized name: Monofer
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained~* administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained
Study: NCT00923910
Drug: KLH
Normalized name: KLH
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
Study: NCT01038323
Drug: Educational with milnacipran
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a series of eight telephone sessions of fibromyalgia related education along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study.
Study: NCT01728246
Drug: Tramadol/Paracetamol (APAP)
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
Study: NCT01728246
Drug: Non-Tramadol/APAP
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Celecoxib 200 mg alone once daily for 4 weeks.
Study: NCT02103465
Drug: Rotigotine
Normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal patch
Study: NCT00773188
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5mg/kg iv or 15mg/kg iv every 3 weeks
Study: NCT00773188
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2 iv according to a standard chemotherapy treatment protocol
Study: NCT00773188
Drug: vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg/m2 iv according to a standard chemotherapy treatment protocol
Study: NCT00047034
Drug: eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00441025
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02114645
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
Study: NCT02114645
Drug: vaginal progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: crinone gel is applied till fetal heart beat is detected
Study: NCT02659085
Drug: Ketamine IV Infusion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
Study: NCT00261339
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02108288
Drug: Carteolol long-acting ophthalmic solution
DrugBank: Carteolol (DB00521)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02108288
Drug: Latanoprost ophthalmic solution
Normalized name: Latanoprost Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01985789
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01985789
Drug: cetirizine
Normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01985789
Drug: desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00665834
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 80 mg from discharge until the end of the study
Study: NCT02661750
Drug: Bowel Preparation
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.
Study: NCT02007941
Drug: CKD-501
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
Study: NCT00215163
Drug: Cognitive-behavioral therapy and paroxetine-CR
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03284164
Drug: Tenofovir Exalidex (TXL)
Normalized name: Tenofovir
DrugBank: Tenofovir exalidex (DB14925)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Tenofovir Exalidex (TXL)
Study: NCT01722240
Drug: Liraglutide 1.8mg
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01516372
Drug: GEn 1200mg
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of Gen administered as a single dose
Study: NCT01516372
Drug: Gen 6000 mg
Normalized name: collagen 6000 MG
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6000 mg of Gen administered as a single dose
Study: NCT01516372
Drug: Moxifloxacin Placebo
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to match Moxifloxacin
Study: NCT01516372
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg Moxifloxacin administered as a single dose
Study: NCT01337570
Drug: Dapivirine
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01518920
Drug: PF-04958242
Normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04958242 0.35 mg oral solution
Study: NCT01518920
Drug: PF-04958242
Normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04958242 0.27 mg oral solution
Study: NCT03514784
Drug: BB-12 with LGG (Higher Dose)
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BB-12 with LGG - Higher Dose (10 billion CFUs)
Study: NCT03514784
Drug: BB-12 with LGG (Lower Dose)
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BB-12 with LGG - Lower Dose (1 billion CFUs)
Study: NCT02588833
Drug: Pegcetacoplan
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Complement (C3) Inhibitor
Study: NCT02738151
Drug: Insulin glargine, 300U/mL
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).
Study: NCT02738151
Drug: Insulin degludec, 100 U/mL
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).~Route of administration: subcutaneous
Study: NCT02047747
Drug: Dacomitinib
Normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
Study: NCT03649711
Drug: Ticagrelor 90mg
Normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor Pill
Study: NCT03649711
Drug: Clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel Pill and a matching placebo to conceal frequency
Study: NCT03649711
Drug: Aspirin 81 mg
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin Pill
Study: NCT02946047
Drug: Ixazomib 1 MG
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
Study: NCT04264000
Drug: platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve
Study: NCT04264000
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve
Study: NCT02946047
Drug: Ixazomib 2 MG
Normalized name: ixazomib 2.3 MG
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.